Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Receivables - Net (2020 - 2025)

Historic Receivables - Net for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $56.6 million.

  • Cytek Biosciences' Receivables - Net rose 759.59% to $56.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.6 million, marking a year-over-year increase of 759.59%. This contributed to the annual value of $60.6 million for FY2024, which is 833.21% up from last year.
  • According to the latest figures from Q3 2025, Cytek Biosciences' Receivables - Net is $56.6 million, which was up 759.59% from $56.2 million recorded in Q2 2025.
  • In the past 5 years, Cytek Biosciences' Receivables - Net registered a high of $60.6 million during Q4 2024, and its lowest value of $24.0 million during Q2 2021.
  • For the 5-year period, Cytek Biosciences' Receivables - Net averaged around $45.5 million, with its median value being $49.2 million (2022).
  • As far as peak fluctuations go, Cytek Biosciences' Receivables - Net skyrocketed by 7516.19% in 2021, and later plummeted by 1003.75% in 2024.
  • Cytek Biosciences' Receivables - Net (Quarter) stood at $29.8 million in 2021, then soared by 64.19% to $48.9 million in 2022, then grew by 14.46% to $55.9 million in 2023, then grew by 8.33% to $60.6 million in 2024, then decreased by 6.53% to $56.6 million in 2025.
  • Its Receivables - Net stands at $56.6 million for Q3 2025, versus $56.2 million for Q2 2025 and $55.0 million for Q1 2025.